

**EARLY TREATMENT SAVES LIVES**

# **NEW PREVENTATIVE MONOCLONAL ANTIBODY THERAPY EVUSHELD**

IT IS A LONG-ACTING MONOCLONAL ANTIBODY  
THERAPY FOR PRE-EXPOSURE PREVENTION.

REDUCES THE RISK OF DEVELOPING COVID-19 BY  
77% IN CLINICAL TRIALS.

THIS PRODUCT IS AUTHORIZED SPECIFICALLY FOR:

- **INDIVIDUALS WHO ARE IMMUNOCOMPROMISED OR ARE TAKING IMMUNOSUPPRESSIVE MEDICATIONS - AND MAY NOT HAVE AN ADEQUATE IMMUNE RESPONSE TO THE VACCINE SUCH AS CANCER PATIENTS OR TRANSPLANT RECIPIENTS.**
- **INDIVIDUALS WITH A HISTORY OF SEVERE ADVERSE REACTIONS TO THE VACCINE OR ITS INGREDIENTS.**

ONLY AUTHORIZED FOR THOSE WHO ARE NOT CURRENTLY  
INFECTED OR HAVE NOT BEEN RECENTLY EXPOSED TO COVID.

CAN PROVIDE THE PROTECTION IMMUNOCOMPROMISED  
AND OTHER MEDICALLY VULNERABLE PEOPLE NEED FOR  
AT LEAST SIX MONTHS.

**FLORIDA LEADS IN PREVENTING AND TREATING COVID-19.**